 NEW YORK, Oct. 12, 2021 GLOBE NEWSWIRE -- Cellectis S.A. NASDAQ: CLLS EURONEXT GROWTH: ALCLS the Company, a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor CAR-T cells and gene therapy programs for genetic diseases, announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancers 36th Annual Meeting SITC 2021, to be held in Washington, D.C. and virtually on November 10 to 14, 2021. 